Book contents
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Chapter D
from Drugs: An A–Z Guide
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Summary
Dalteparin is an LMWH with greater anti-factor Xa activity than anti-IIa (antithrombin) activity, which theoretically makes it more effective at preventing thrombin formation than standard (unfractionated) heparin with an equal anti-factor Xa and anti-IIa ratio.
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 92 - 114Publisher: Cambridge University PressPrint publication year: 2025